Cyclophosphamide, Cisplatin, and Leuprolide Acetate in Patients with Debulked Stage III or IV Ovarian Carcinoma

Lisa D. Erickson, Lynn C. Hartmann, John Q. Su, Skott N J Nielsen, Delano M. Pfeifel, Richard M. Goldberg, Ralph Levitt, C. Robert Stanhope

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

A phase II study of cyclophosphamide, cisplatin, and leuprolide acetate after debulking of stage III or IV ovarian carcinoma was conducted in 33 patients through a cooperative group study involving 11 institutions. The intent was to determine whether the addition of a gonadotropin-releasing hormone analogue would alter the response rates and toxicity profile of cyclophosphamide and cisplatin in patients with advanced ovarian cancer. Twenty-nine patients completed all 6 planned cycles. Of the 19 patients who had second-look laparotomy, 12 had persistent disease and 7 were negative for disease. The use of a gonadotropin-releasing hormone with combined chemotherapy did not alter the toxicity profile or the effectiveness of chemotherapy when comparisons were made with historical controls.

Original languageEnglish (US)
Pages (from-to)196-200
Number of pages5
JournalGynecologic Oncology
Volume54
Issue number2
DOIs
StatePublished - Aug 1994

Fingerprint

Leuprolide
Cyclophosphamide
Cisplatin
Carcinoma
Gonadotropin-Releasing Hormone
Drug Therapy
Ovarian Neoplasms
Laparotomy

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

Erickson, L. D., Hartmann, L. C., Su, J. Q., Nielsen, S. N. J., Pfeifel, D. M., Goldberg, R. M., ... Stanhope, C. R. (1994). Cyclophosphamide, Cisplatin, and Leuprolide Acetate in Patients with Debulked Stage III or IV Ovarian Carcinoma. Gynecologic Oncology, 54(2), 196-200. https://doi.org/10.1006/gyno.1994.1192

Cyclophosphamide, Cisplatin, and Leuprolide Acetate in Patients with Debulked Stage III or IV Ovarian Carcinoma. / Erickson, Lisa D.; Hartmann, Lynn C.; Su, John Q.; Nielsen, Skott N J; Pfeifel, Delano M.; Goldberg, Richard M.; Levitt, Ralph; Stanhope, C. Robert.

In: Gynecologic Oncology, Vol. 54, No. 2, 08.1994, p. 196-200.

Research output: Contribution to journalArticle

Erickson, LD, Hartmann, LC, Su, JQ, Nielsen, SNJ, Pfeifel, DM, Goldberg, RM, Levitt, R & Stanhope, CR 1994, 'Cyclophosphamide, Cisplatin, and Leuprolide Acetate in Patients with Debulked Stage III or IV Ovarian Carcinoma', Gynecologic Oncology, vol. 54, no. 2, pp. 196-200. https://doi.org/10.1006/gyno.1994.1192
Erickson, Lisa D. ; Hartmann, Lynn C. ; Su, John Q. ; Nielsen, Skott N J ; Pfeifel, Delano M. ; Goldberg, Richard M. ; Levitt, Ralph ; Stanhope, C. Robert. / Cyclophosphamide, Cisplatin, and Leuprolide Acetate in Patients with Debulked Stage III or IV Ovarian Carcinoma. In: Gynecologic Oncology. 1994 ; Vol. 54, No. 2. pp. 196-200.
@article{619f7e85f5be4e35af107e6b31f67fd6,
title = "Cyclophosphamide, Cisplatin, and Leuprolide Acetate in Patients with Debulked Stage III or IV Ovarian Carcinoma",
abstract = "A phase II study of cyclophosphamide, cisplatin, and leuprolide acetate after debulking of stage III or IV ovarian carcinoma was conducted in 33 patients through a cooperative group study involving 11 institutions. The intent was to determine whether the addition of a gonadotropin-releasing hormone analogue would alter the response rates and toxicity profile of cyclophosphamide and cisplatin in patients with advanced ovarian cancer. Twenty-nine patients completed all 6 planned cycles. Of the 19 patients who had second-look laparotomy, 12 had persistent disease and 7 were negative for disease. The use of a gonadotropin-releasing hormone with combined chemotherapy did not alter the toxicity profile or the effectiveness of chemotherapy when comparisons were made with historical controls.",
author = "Erickson, {Lisa D.} and Hartmann, {Lynn C.} and Su, {John Q.} and Nielsen, {Skott N J} and Pfeifel, {Delano M.} and Goldberg, {Richard M.} and Ralph Levitt and Stanhope, {C. Robert}",
year = "1994",
month = "8",
doi = "10.1006/gyno.1994.1192",
language = "English (US)",
volume = "54",
pages = "196--200",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Cyclophosphamide, Cisplatin, and Leuprolide Acetate in Patients with Debulked Stage III or IV Ovarian Carcinoma

AU - Erickson, Lisa D.

AU - Hartmann, Lynn C.

AU - Su, John Q.

AU - Nielsen, Skott N J

AU - Pfeifel, Delano M.

AU - Goldberg, Richard M.

AU - Levitt, Ralph

AU - Stanhope, C. Robert

PY - 1994/8

Y1 - 1994/8

N2 - A phase II study of cyclophosphamide, cisplatin, and leuprolide acetate after debulking of stage III or IV ovarian carcinoma was conducted in 33 patients through a cooperative group study involving 11 institutions. The intent was to determine whether the addition of a gonadotropin-releasing hormone analogue would alter the response rates and toxicity profile of cyclophosphamide and cisplatin in patients with advanced ovarian cancer. Twenty-nine patients completed all 6 planned cycles. Of the 19 patients who had second-look laparotomy, 12 had persistent disease and 7 were negative for disease. The use of a gonadotropin-releasing hormone with combined chemotherapy did not alter the toxicity profile or the effectiveness of chemotherapy when comparisons were made with historical controls.

AB - A phase II study of cyclophosphamide, cisplatin, and leuprolide acetate after debulking of stage III or IV ovarian carcinoma was conducted in 33 patients through a cooperative group study involving 11 institutions. The intent was to determine whether the addition of a gonadotropin-releasing hormone analogue would alter the response rates and toxicity profile of cyclophosphamide and cisplatin in patients with advanced ovarian cancer. Twenty-nine patients completed all 6 planned cycles. Of the 19 patients who had second-look laparotomy, 12 had persistent disease and 7 were negative for disease. The use of a gonadotropin-releasing hormone with combined chemotherapy did not alter the toxicity profile or the effectiveness of chemotherapy when comparisons were made with historical controls.

UR - http://www.scopus.com/inward/record.url?scp=0027934299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027934299&partnerID=8YFLogxK

U2 - 10.1006/gyno.1994.1192

DO - 10.1006/gyno.1994.1192

M3 - Article

VL - 54

SP - 196

EP - 200

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -